Navigation Links
GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health

SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- GlySens Incorporated announced today that it has been awarded a two-year, two million dollar grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH).  The grant is intended to support human clinical evaluation of the GlySens second generation ICGM™ long term implantable glucose monitoring system.  Final preparations for launch of the trial are underway, and enrollment is expected to begin before the end of 2014.

"We are extremely pleased and grateful to have the support of NIDDK and the NIH as we take these next steps in the development of the GlySens ICGM system," said Joseph Lucisano, PhD, GlySens President and CEO.  "As appreciation continues to grow for the potential of continuous glucose monitoring to make a real difference in the lives of people with diabetes, the need to provide an effective, widely acceptable, patient-friendly product has never been greater.  We believe that our long term system approach, with its fully implantable sensor intended to operate continuously for one year without need for replacement, will provide the convenience and ease of use that patients desire and foster widespread application of continuous glucose monitoring in diabetes care.  The long-standing engagement of the NIH with our research program has provided tremendous value in helping us ensure that our approach aims to serve a broad range of patient needs while we also maintain the highest level of scientific rigor in our efforts.  As with our other previous NIH sponsored projects, including the completed human clinical evaluation of the first generation ICGM system, we look forward to conducting this upcoming clinical trial with NIH support."

About GlySens Incorporated
GlySens Incorporated is a privately held corporation devoted to developing the world's first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes.  The GlySens fully implanted sensor—demonstrated up to 18-month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions.  In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance.  For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGM™ system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms.  Additional information is available at

ICGM is a trademark of GlySens Incorporated.


Research reported in this release was supported by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under grant number R44DK077254.  The content of this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

SOURCE GlySens Incorporated
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. West Health Investment Fund invests in GlySens and RxAnte
2. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
3. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
4. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
5. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
6. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
7. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
8. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
9. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
10. Proacta Incorporated Announces IND Allowance for PR610
11. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
Post Your Comments:
(Date:10/8/2019)... DANA POINT, Calif. (PRWEB) , ... October 08, ... ... of Niguel Coast Oral & Facial Surgery raise awareness of their advanced dental ... treatment. The Dana Point, CA oral surgeons welcome patients with heart conditions, diabetes, ...
(Date:10/8/2019)... ... October 08, 2019 , ... Respected oral and maxillofacial surgeon, ... & Maxillofacial Surgery. This cutting-edge practice serves both Washington, PA and Steubenville, OH ... to predictable jaw surgery with 3D imaging. Dr. Humberger was honored to join ...
(Date:10/8/2019)... ... October 08, 2019 , ... Fresno resident Regina Tanner has been selected ... living donor honoree. Regina will walk alongside the float, Light in the Darkness, during ... nurse and attorney, became a living organ donor in the fall of 2016 when ...
Breaking Medicine Technology:
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... Knotty Roller, ... roller case, quickly broke its campaign goal– raising more than $20,000 in only eleven ... from the crowdfunding community, who’ll be the first to enjoy the ease of use ...
(Date:10/17/2019)... ... October 17, 2019 , ... A clinical article reviewing the long-term performance ... Paper Award at Plastic Surgery - The Meeting 2019 in San Diego last month. ... was authored by Larry S. Nichter, M.D., Robert A. Hardesty, M.D., and Gregg M. ...
(Date:10/15/2019)... ... October 14, 2019 , ... Khalieghya Dandie-Evans, a liver ... ride atop the Donate Life Rose Parade® float in the 131st Rose Parade® on ... tissue donation across Northern California and Northern Nevada, the organization’s service area. , Khalieghya, ...
(Date:10/15/2019)... FALLS CHURCH, Va. (PRWEB) , ... October 15, ... ... Combination Products:, Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, ... does the recent Instructions for Use (IFU) guidance have on new drug applications ...
(Date:10/15/2019)... (PRWEB) , ... October 15, 2019 , ... Genomenon® ... partnership with SOPHiA GENETICS that includes incorporating the Mastermind® Genomic Search ... puts the most up-to-date genomic research at the fingertips of clinical researchers performing genomic ...
Breaking Medicine News(10 mins):